Eloxx Pharma restarts mid-stage cystic fibrosis study in the U.S.

Eloxx Pharmaceuticals (NASDAQ:ELOX) jumps 9% premarket in reaction to the resumption of enrollment in its Phase 2 clinical trial for ELX-02 in cystic fibrosis in the U.S. which was temporarily paused in response to the COVID-19 pandemic.

On June 17, enrollment resumed in a Phase 2 cystic fibrosis trial in Europe and Israel too.

“Our highest priority is to complete the Phase 2 proof of concept clinical trial program and report top line data as soon as possible,” said Dr. Gregory Williams, CEO of Eloxx.

https://seekingalpha.com/news/3604543-eloxx-pharma-restarts-mid-stage-cystic-fibrosis-study-in-u-s